Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C19H29N3O4S2 and a molecular weight of approximately 427.58 g/mol[1][6]. It features a benzene ring fused to a thiazine ring system with sulfonamide and piperazine substituents. The drug is listed as an experimental agent in chemical databases but does not have an established clinical indication or detailed mechanism of action reported in public sources[8]. Its structure suggests it may have been investigated as a research tool or potential drug candidate; however, no information on its pharmacological targets or therapeutic use is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide.